Vera Therapeutics (VERA)
(Delayed Data from NSDQ)
$36.62 USD
-0.95 (-2.53%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $36.60 -0.02 (-0.05%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VERA 36.62 -0.95(-2.53%)
Will VERA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VERA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VERA
Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex
Wall Street Analysts Believe Vera Therapeutics, Inc. (VERA) Could Rally 86.76%: Here's is How to Trade
VERA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -34.74% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA)
Down -38.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA)
Down -37.74% in 4 Weeks, Here's Why Vera Therapeutics, Inc. (VERA) Looks Ripe for a Turnaround
Other News for VERA
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics Appoints Christy Oliger to Board
Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)